FDA approves MFLUSIVA, its first mRNA flu vaccine, with distinct age-based pathways
Regulatory / securities filing · U.S. Food and Drug Administration
Source published: · Event / reporting date: 2026-08-05
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
FDA approved MFLUSIVA, an mRNA influenza vaccine for adults 50 and older. Ages 50–64 received traditional approval based on clinical efficacy evidence; ages 65 and older received accelerated approval based on antibody responses versus a high-dose comparator, requiring confirmation of clinical benefit. FDA’s review reports overall relative vaccine efficacy of 26.6% versus a standard-dose comparator in the Phase 3 P304 trial.
Why it may matter
The decision extends mRNA vaccination into influenza while showing why accelerated approval in older adults must be distinguished from confirmed clinical benefit.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections